Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico

References

• Bartone PT, Roland RR, Picano JJ, Williams TJ. Psychological hardiness predicts success in U.S. Army special forces candidates. Int J Sel Assess. 2008;16:78–81. doi:10.1111/j.1468-2389.2008.00412.x.
   Web of Science ®Google Scholar
• Hanwella R, de Silva V. Mental health of special forces personnel deployed in battle. Soc Psych Psych Epid. 2012;47:1343–51. doi:10.1007/s00127-011-0442-0.
   PubMed Web of Science ®Google Scholar
• Hing M, Cabrera J, Barstow C, Forsten R. Special operations forces and incidence of post traumatic stress disorder symptoms. J Spec Oper Med. 2012;12:23–35.
   PubMedGoogle Scholar
• Greer N, Sayer NA, Spoont M, Taylor BC, Ackland PE, MacDonald R, McKenzie L, Rosebush C, Wilt TJ. Prevalence and severity of psychiatric disorders and suicidal behavior in service members and veterans with and without traumatic brain injury: systematic review. J Head Trauma Rehabil. 2020;35:1–13.
   PubMed Web of Science ®Google Scholar
• Cantor JB, Ashman T, Gordon W, Ginsberg A, Engmann C, Egan M, Spielman L, Dijkers M, Flanagan S. Fatigue after traumatic brain injury and its impact on participation and quality of life. J Head Trauma Rehabil. 2008;23:41–51.
   PubMed Web of Science ®Google Scholar
• Rocklein Kemplin K, Paun O, Godbee DC, Brandon JW. Resilience and Suicide in Special Operations Forces: state of the Science via Integrative Review. J Spec Oper Med. 2019;19:57–66.
   PubMedGoogle Scholar
• Kashiwa A, Sweetman MM, Helgeson L. Occupational therapy and veteran suicide: a call to action. Am J Occup Ther. 2017;71:1–6. doi:10.5014/ajot.2017.023358.
   Web of Science ®Google Scholar
• Wolfe-Clark AL, Bryan CJ. Integrating two theoretical models to understand and prevent military and Veteran suicide. Armed Forces Soc. 2017;43:478–99. doi:10.1177/0095327X16646645.
   Web of Science ®Google Scholar
• Starr B. US special ops suicides triple in 2018, as military confronts the issue. CNN. 2019 Feb 2 [accessed 2023 May 7]. https://www.cnn.com/2019/02/02/politics/socom-military-suicide-spike2018/index.html#:~:text=Special%20Operations%20units%20saw%2022,to%20CNN%20by%20the%20command.
   Google Scholar
• Watts BV, Schnurr PP, Mayo L, Young-Xu Y, Weeks WB, Friedman MJ. Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. J Clin Psychiatry. 2013;74:e541–e50. doi:10.4088/JCP.12r08225.
   PubMed Web of Science ®Google Scholar
• Steenkamp MM, Litz BT, Hoge CW, Marmar CR. Psychotherapy for military-related PTSD: a review of randomized clinical trials. JAMA. 2015;314:489–500. doi:10.1001/jama.2015.8370.
   PubMed Web of Science ®Google Scholar
• Schnurr PP, Chard KM, Ruzek JI, Chow BK, Resick PA, Foa EB, Marx BP, Friedman MJ, Bovin MJ, Caudle KL, et al. Comparison of prolonged exposure vs cognitive processing therapy for treatment of posttraumatic stress disorder among US veterans: a randomized clinical trial. JAMA Network Open. 2022;5:e2136921. doi:10.1001/jamanetworkopen.2021.36921.
   PubMed Web of Science ®Google Scholar
• Mott JM, Mondragon S, Hundt NE, Beason-Smith M, Grady RH, Teng EJ. Characteristics of U.S. Veterans who begin and complete prolonged exposure and cognitive processing therapy for PTSD. J Trauma Stress. 2014;27:265–73.
   PubMed Web of Science ®Google Scholar
• Najavits LM. The problem of dropout from “gold standard” PTSD therapies. F1000Prime Rep. 2015;7. doi:10.12703/P7-43.
   PubMedGoogle Scholar
• Bisson JI, Ehlers A, Matthews R, Pilling S, Richards D, Turner S. Psychological treatments for chronic post-traumatic stress disorder. Systematic review and meta-analysis. Br J Psychiatry. 2007;190:97–104. doi:10.1192/bjp.bp.106.021402.
   PubMed Web of Science ®Google Scholar
• Puetz TW, Youngstedt SD, Herring MP, Hashimoto K. Effects of pharmacotherapy on combat-related PTSD, anxiety, and depression: a systematic review and meta-regression analysis. PLos One. 2015;10:e0126529. doi:10.1371/journal.pone.0126529.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Davis LL, Neylan TC, Raskind A, Schnurr M, PP SM, Vessicchio J, Shiner B, Gleason TD, Huang GD, et al. It is Time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: a consensus statement of the PTSD Psychopharmacology Working Group. Biol Psychiatry. 2017;82:e51–e59. doi:10.1016/j.biopsych.2017.03.007.
   PubMed Web of Science ®Google Scholar
• Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry. 2007;68:711–20. doi:10.4088/JCP.v68n0508.
   PubMed Web of Science ®Google Scholar
• Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments. Depress Anxiety. 2016;33:792–806. doi:https://doi.org/10.1002/da.22511.
   PubMed Web of Science ®Google Scholar
• Gutner CA, Galovski T, Bovin MJ, Schnurr PP. Emergence of Transdiagnostic Treatments for PTSD and Posttraumatic Distress. Curr Psychiatry Rep. 2016;18:95. doi:10.1007/s11920-016-0734-x.
   PubMed Web of Science ®Google Scholar
• Varkovitzky RL, Sherrill AM, Reger GM. Effectiveness of the unified protocol for transdiagnostic treatment of emotional disorders among veterans with posttraumatic stress disorder: a Pilot Study. Behav Modif. 2018;42:210–30.
   PubMed Web of Science ®Google Scholar
• Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68:71–78. doi:10.1001/archgenpsychiatry.2010.116.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11:642–51. doi:10.1038/nrn2884.
   PubMed Web of Science ®Google Scholar
• Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67:1735–40. doi:10.4088/JCP.v67n1110.
   PubMed Web of Science ®Google Scholar
• Bogenschutz MP. Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin. CDAR. 2013;6:17–29. doi:10.2174/15733998113099990002.
   Google Scholar
• Bogenschutz MP, Johnson MW. Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:250–58.
   PubMed Web of Science ®Google Scholar
• Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28:983–92. doi:10.1177/0269881114548296.
   PubMed Web of Science ®Google Scholar
• Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. 2017;43:55–60. doi:10.3109/00952990.2016.1170135.
   PubMed Web of Science ®Google Scholar
• Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E. Reviewing the Potential of Psychedelics for the Treatment of PTSD. Int J Neuropsychopharmacol. 2020;23:385–400. doi:10.1093/ijnp/pyaa018.
   PubMed Web of Science ®Google Scholar
• Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot’alora GM, Garas W, Paleos C, Gorman I, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:1025–33. doi:10.1038/s41591-021-01336-3.
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry. 2016;3:481–88.
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, Holland J, Hamilton S, Yazar-Klosinski B, Emerson A, et al. 3,4 methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose response, phase 2 clinical trial. Lancet Psychiatry. 2018;5:486–97. doi:10.1016/S2215-0366(18)30135-4.
   PubMed Web of Science ®Google Scholar
• Davis AK, Averill LA, Sepeda ND, Barsuglia JP, Amoroso T. Psychedelic treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans. Chronic Stress. 2020;4:2470547020939564.
   Google Scholar
• U.S. Department of Justice. Controlled substances – alphabetical order. Washington DC. Drug Enforcement Administration. Diversion Control Division Drug & Chemical Evaluation Section. 2023 Apr 10 [accessed 2023 May 3]. https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf
   Google Scholar
• Barsuglia JP, Polanco M, Palmer R, Malcolm BJ, Kelmendi B, Calvey T. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder. Prog Brain Res. 2018;242:121–58.
   PubMed Web of Science ®Google Scholar
• Gupta S. Intention-to-treat concept: a review. Perspect Clin Res. 2011;2:109–12.
   PubMedGoogle Scholar
• Diener E, Emmons RA, Larsen RJ, Griffin S. The satisfaction with life scale. J Pers Assess. 1985;49:71–75.
   PubMed Web of Science ®Google Scholar
• Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The posttraumatic stress disorder checklist for DSM-5 (PCL-5): development and initial psychometric evaluation. J Trauma Stress. 2015;28:489–98.
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41:1284–92. doi:10.1097/01.MLR.0000093487.78664.3C.
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JBW, Monohan PO, Lowe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146:317–25. doi:10.7326/0003-4819-146-5-200703060-00004.
   PubMed Web of Science ®Google Scholar
• Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016;39:24–31. doi:10.1016/j.genhosppsych.2015.11.005.
   PubMed Web of Science ®Google Scholar
• Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2:297–307. doi:10.1016/S1389-9457(00)00065-4.
   PubMed Web of Science ®Google Scholar
• Bond FW, Hayes SC, Baer RA, Carpenter KM, Guenole N, Orcutt HK, Waltz T, Zettle RD. Preliminary psychometric properties of the acceptance and action Questionnaire-II: a revised measure of psychological inflexibility and experiential avoidance. Behav Ther. 2011;42:676–88. doi:10.1016/jbeth.2011.03.007.
   PubMed Web of Science ®Google Scholar
• Sheehan DV. The anxiety disease. New York: Charles Scribner and Sons; 1983.
   Google Scholar
• Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int’l J Psychiatry Med. 1997;27:93–105.
   PubMed Web of Science ®Google Scholar
• Hays RD, Sherbourne CD, Mazel R. User’s Manual for the Medical Outcomes Study (MOS) core measures of health-related quality of life. Santa Monica, CA: RAND Corporation; 1995. https://rand.org/pubs/monograph_reports/MR162.html.
   Google Scholar
• King PR, Donnelly KT, Donnelly JP, Dunnam M, Warner G, Kittleson CJ, Bradshaw CB, Alt M, Meier ST. Psychometric study of the neurobehavioral symptom inventory. JRRD. 2012;49:879–88. doi:10.1682/JRRD.2011.03.0051.
   PubMed Web of Science ®Google Scholar
• Harmon-Jones C, Bastian B, Harmon-Jones E, Aleman A. The discrete emotions questionnaire: a new tool for measuring state self-reported emotions. PLos One. 2016;11:e0159915. doi:10.1371/journal.pone.0159915.
   PubMed Web of Science ®Google Scholar
• Joiner TE Jr, Pfaff JJ, Acres JG. A brief screening tool for suicidal symptoms in adolescents and young adults in general settings: reliability and validity from the Australian national general practice youth suicide prevention project. Behav Res Ther. 2002;40:471–81. doi:10.1016/S0005-7967(01)00017-1.
   PubMed Web of Science ®Google Scholar
• von Glischinksi M, Teismann T, Prinz S, Gebauer JE, Hirschfeld G. Depressive symptom inventory suicidality subscale: optimal cut points for clinical and non-clinical samples. Clin Psychol Psychother. 2016;23:543–49. doi:10.1002/cpp.2007.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical experiences having substantial and sustained personal meaning and spiritual significance. J Psychopharmacol. 2006;187:268–83. doi:10.1007/s00213-006-0457-5.
   Web of Science ®Google Scholar
• Hendrickson RC, Schindler AG, Pagulayan KF. Untangling PTSD and TBI: challenges and strategies in clinical care and research. Curr Neurol Neurosci Rep. 2018;18:106. doi:https://doi.org/10.1007/s11910-018-0908-5.
   PubMed Web of Science ®Google Scholar
• Kaplan GB, Leite-Morris KA, Wang L, Rumbika KK, Heinrichs SC, Zeng X, Wu L, Arena DT, Teng YD. Pathophysiological bases of comorbidity: traumatic brain injury and post-traumatic stress disorder. J Neurotrauma. 2018;35:210–25. doi:10.1089/neu.2016.4953.
   PubMed Web of Science ®Google Scholar
• Olson DE. Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics. J Exp Neurosci. 2018;12:1179069518800508. doi:10.1177/1179069518800508.
   Web of Science ®Google Scholar
• Porter KE, Stein MB, Martis B, Avallone KM, McSweeney LB, Smith ER, Simon NM, Gargan S, Liberzon I, Hoge CW, et al. Postconcussive symptoms (PCS) following combat-related traumatic brain injury (TBI) in Veterans with posttraumatic stress disorder (PTSD): influence of TBI, PTSD, and depression on symptoms measured by the Neurobehavioral Symptom Inventory (NSI). J Psychiatr Res. 2018;102:8–13.
   PubMed Web of Science ®Google Scholar
• Spadoni AD, Huang M, Simmons AN. Emerging Approaches to neurocircuits in PTSD and TBI: imaging the Interplay of Neural and Emotional Trauma. Curr Top Behav Neurosci. 2018;38:163–92. doi:10.1007/7854_2017_35.
   PubMedGoogle Scholar
• Vargas MV, Meyer R, Avanes AA, Rus M, Olson DE. Psychedelics and other psychoplastogens for treating mental illness. Frontiers In Psychiatry. 2021;12:727117.
   PubMed Web of Science ®Google Scholar